NASDAQ · GMAB
Genmab A/S ADS
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GMAB: Nov 05, 2026
Genmab A/S ADS is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $0.37. The reported EPS for the same quarter last year was $0.65.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.37 | $0.49 | $0.30 | 5 |
| Dec 2026 | $0.33 | $0.46 | $0.24 | 4 |
| Mar 2027 | $0.25 | $0.35 | $0.18 | 4 |
| Jun 2027 | $0.46 | $0.59 | $0.36 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · BNK Invest · Zacks- MarketBeat · Oct 28, 5:04 PM EDTGenmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer LaunchesGenmab A/S (NASDAQ:GMAB) said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops. Chief Exec
- RTTNews · Oct 28, 3:16 PM EDTBiotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%(RTTNews) – Shares of several biotech companies moved higher following quarterly financial results, clinical trial developments and business updates. Genmab reported positive Phase 3 results for its cancer drug combination, Pulmonx posted improved quarterly results, Axogen and Or
- RTTNews · Oct 28, 11:29 AM EDTGenmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up(RTTNews) – Genmab A/S (GMAB) reported positive results form a Phase 3 trial evaluating Petosemtamab plus Keytruda (pembrolizumab) as a first-line treatment for patients with PD-L1 positive recurrent or metastatic head and neck cancer. The combination significantly improved overa
- BNK Invest · Oct 27, 6:47 AM EDTGenmab Reaches Analyst Target PriceIn recent trading, shares of Genmab A/S (Symbol: GMAB) have crossed above the average analyst 12-month target price of $43.85, changing hands for $44.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation
- Zacks · Oct 26, 10:25 AM EDTIncyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyINCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
- RTTNews · Oct 26, 8:02 AM EDTGenmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer(RTTNews) – Genmab (GMAB) reported updated Phase 2 results showing that Potesemtamab in combination with Pembrolizumab delivered encouraging survival and response rates in patients with first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma.
- RTTNews · Oct 26, 4:54 AM EDTGenmab's Petosemtamab Delivers Strong Response Rates In Metastatic Colorectal Cancer(RTTNews) – Genmab (GMAB) reported updated Phase 2 data showing that Petosemtamab, when combined with standard chemotherapy, continued to demonstrate encouraging response rates in patients with metastatic colorectal cancer (mCRC). The findings were presented at the ESMO Congress
- RTTNews · Oct 24, 8:27 AM EDTGenmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer(RTTNews) – Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring a KRAS G12D mutation, a population with significant unmet medical needs.
- RTTNews · Oct 23, 3:00 PM EDTBiotech Stocks On Investor Radar – BOLT +66%, LYCA +33%, LUCD, GMAB(RTTNews) – Shares of several biotech companies moved higher following corporate, financing and clinical developments. Bolt Biotherapeutics gained after announcing a reverse merger with Prana Therapies and a $120 million private placement, Lycia Therapeutics surged in its Nasdaq
- Fintel · Oct 23, 12:10 PM EDTGenmab A/S Announces Positive Topline Results from Phase 3 RAINFOL-02 TrialGenmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with pl
- RTTNews · Oct 13, 7:25 AM EDTGenmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year(RTTNews) – Genmab (GMAB) announced that worldwide net sales of DARZALEX (daratumumab), as reported by partner Johnson & Johnson (JNJ), totaled $4.24 billion during the third quarter of 2026, up from $3.67 billion in the third quarter of 2025.
- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Genmab A/S ADS from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.